Alzheimer Therapeutics Market

Alzheimer Therapeutics Market Size to Attain USD 33.62 Billion by 2034

Healthcare
/ /

The global Alzheimer therapeutics market size is projected to experience robust growth, with expected market valuation hitting USD 33.62 billion by 2034 from USD 6.49 billion in 2025, growing at a CAGR of 20.06% between 2025 and 2034. This surge is primarily fueled by an increasing elderly population worldwide and revolutionary advances in disease-modifying therapies […]

Case Study: Biogen’s Leqembi Redefines Alzheimer’s Treatment Landscape: A Breakthrough in Disease Modification and Global Access

Case Studies
/ /

Headquarters: Cambridge, Massachusetts, U.S.Offering: Leqembi (Lecanemab) – Amyloid Beta-directed Antibody Case Study Biogen Inc., a leading biotechnology company specializing in neurodegenerative and rare diseases, achieved a breakthrough in Alzheimer’s therapeutics through the global expansion of Leqembi (Lecanemab), its amyloid beta-directed antibody developed in collaboration with Eisai Co., Ltd. Following full approval by the U.S. Food

Scroll to Top